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Abstract 
Study objectives: That sleep deprivation increases the brain expression of various clock 
genes has been well documented. Based on these and other findings we hypothesized that 
clock genes not only underlie circadian rhythm generation but are also implicated in sleep 
homeostasis. However, long time lags have been reported between the changes in the clock 
gene mRNA levels and their encoded proteins. It is therefore crucial to establish whether 
also protein levels increase within the time frame known to activate a homeostatic sleep 
response. We report on the central and peripheral effects of sleep deprivation on PERIOD-2 
(PER2) protein both in intact and SCN-lesioned mice.  
Design: In vivo and in situ PER2 imaging during baseline, sleep deprivation, and recovery. 
Settings: Mouse sleep-recording facility. 
Participants: Per2::Luciferase knock-in mice. 
Interventions: N/A 
Measurements and Results: Six-hour sleep deprivation increased PER2 not only in the brain 
but also in liver and kidney. Remarkably, the effects in the liver outlasted those observed in 
brain. Within the brain the increase in PER2 concerned the cerebral cortex mainly, while 
leaving SCN levels unaffected. Against expectation, sleep deprivation did not increase PER2 
in the brain of arrhythmic SCN-lesioned mice due to higher PER2 levels in baseline. In 
contrast, liver PER2 levels did increase in these mice similar to the sham- and partially-
lesioned controls. 
Conclusions: Our results stress the importance of considering both sleep-wake dependent 
and circadian processes when quantifying clock-gene levels. Because sleep deprivation alters 
PER2 in the brain as well as in the periphery, it is tempting to speculate that clock genes 
constitute a common pathway mediating the shared and well-known adverse effects of both 
chronic sleep loss and disrupted circadian rhythmicity on metabolic health. 
 
Keywords: PER2 protein, in vivo imaging, bioluminescence, homeostasis, sleep deprivation, 
clock genes, cerebral cortex, hippocampus, cerebellum, Purkinje cells, SCN-lesion, circadian.  
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Introduction 
The timing and quality of both sleep and wakefulness depend on the interaction of two 
processes. A sleep-wake driven process monitors and controls homeostatic sleep need, 
while a circadian process generates a sleep-wake independent wake-promoting signal. The 
circadian wake-promoting signal is thought to oppose homeostatic sleep need thereby 
determining the time-of-day sleep occurs.
1
 Studies aimed at dissecting the respective 
contributions of sleep-wake dependent and circadian factors to sleep-wake regulation are 
hampered by the fact that many aspects of sleep are directly or indirectly affected by both 
processes. Accumulating evidence shows that even the so-called clock genes, long thought 
to encode circadian time information exclusively and therefore widely used as circadian 
state variables, are also implicated in the homeostatic process; i.e., conferring information 
concerning time-spent-awake (and asleep).
2
 
 The notion that clock genes play a role in the homeostatic aspect of sleep regulation 
comes from three types of observations. First, altered sleep homeostasis was observed in 
animals, including humans, carrying clock gene mutations or polymorphisms.
3-12
 In these 
studies the response to sleep deprivation in terms of increased sleep duration and/or EEG 
delta power during NREM sleep, a widely used state variable of the sleep homeostatic 
process,
13
 differed from those observed in controls. A second type of observation concerns 
the effects of sleep deprivation on the specific DNA-binding of NPAS2 and BMAL1 to the E-
box motives of specific target genes, among which the clock gene Per2.
14
 This study 
demonstrates that extended wakefulness directly affects the core clock machinery. Lastly, 
and likely related to the previous observation, the expression of a number of core circadian 
transcripts changes as a function of time-spent-awake (or time-spent-asleep). Among those, 
Per2 mRNA levels in the brain are reliably and predictably increased by sleep deprivation 
under a number of conditions.
8,15-18
 
 From circadian time course analyses it is known that 6- to 8h lags exist between the 
time at which mRNA and protein levels peak for many clock genes.
19
 These long time lags 
have been attributed to the many post-transcriptional and -translational processes known to 
modify the stability and nuclear entry of clock genes among other mechanisms.
19-21
 In the 
mouse robust homeostatic responses in a variety of sleep variables can, however, already be 
observed after sleep deprivations of 6h.
22,23
 If clock genes are to play a functional role in 
sleep homeostasis, their protein product should increase within such time frame. To date, 
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studies quantifying clock gene protein levels after sleep deprivation are lacking and a main 
aim of the present study is therefore to determine the dynamics of the protein levels of the 
clock gene Per2 during sleep deprivation and recovery sleep. In addition, we have previously 
shown that the wake-dependent increase in Per2 expression is modulated by circadian 
factors.
18
 Hence, a further goal is to determine the influence of lesioning the supra-
chiasmatic nuclei (SCN), the central circadian pacemaker, on the sleep-deprivation induced 
increase of PER2. We expect to observe this increase also in behaviourally arrhythmic mice. 
As accumulating evidence suggests that sleep deprivation not only affects gene expression in 
the brain but also in the periphery,
16,24-26
 a last aim was to establish whether PER2 levels in 
the liver and kidney are affected as well. 
 To achieve these goals we used Per2::Luciferase (Per2
Luc
) knock-in mice,
27
 to image 
PER2 protein variations in the whole living mouse. We found that PER2 protein increases 
after sleep deprivation not only in the brain but also in the liver and the kidney, albeit with 
tissue specific dynamics. Brain immunohistochemistry established that sleep deprivation 
targeted PER2 levels in layers IV and V of the cerebral cortex, while levels in SCN remained 
unperturbed. These results demonstrate for the first time that in the brain, sleep deprivation 
rapidly increases PER2 (within 3h) and thus that the protein follows the changes in mRNA 
more closely as compared to the circadian relationship between the two. Against 
expectation, the sleep-deprivation induced increase of PER2 in the brain was smaller in SCN-
lesioned mice while in the liver PER2 was again higher than baseline similar to sham- and 
partially-lesioned control mice. Equally unexpected was the finding that in some SCN-
lesioned mice we could still identify circadian rhythmicity in PER2 despite an absence of a 
circadian organization of locomotor activity. Illustrated for Per2, these results stress the 
importance of considering both sleep-wake dependent and circadian processes when 
quantifying clock gene levels in vivo. 
 
 
Experimental procedures 
Animals, housing conditions and sleep deprivation (SD):  All animals were kept under a 12h 
light/ 12h-dark cycle (LD12:12; lights on at 09:00, 110lx) and were singly housed with food 
and water available ad libitum. We use Zeitgeber time (ZT) to indicate time-of-day with ZT0 
(or ZT24) marking light onset and ZT12 dark onset. Cages were placed in a sound attenuated 
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and temperature controlled recording room (25°C). Both female and male mice were used. 
Animals were sleep-deprived (SD) by what is referred to as ‘gentle handling‘ 
28
. 
 C57BL/6J (B6) mice heterozygous for the Per2::Luciferase knock-in construct (Per2
Luc
; 
kindly provided by Dr. J.S. Takahashi, University of Texas, Southwestern Medical Center, TX, 
USA) were bred in our facility and all experiments were approved by the Ethical Committee 
of the State of Vaud Veterinary Office, Switzerland. PCR genotyping was done as described 
previously.
27
 
 
In vivo PER2 bioluminescence imaging: Mice heterozygous for the Per2
Luc
 construct 
displayed lower levels of bioluminescence (data not shown) and all experiments were 
therefore performed in homozygous Per2
Luc 
mice only. The luciferase substrate, D-luciferin 
(Prolume Ltd, Pinetop, AZ, USA; 35mg/mL diluted in ACSF, pH 7.3), was delivered using 
osmotic mini pumps (model 1002, Alzet, Cupertino, CA, USA; release rate 0.25ʅL/h over 14 
days according to manufacturer’s specifications). For brain delivery of D-luciferin, a cannula 
(Brain infusion kit1, Alzet) was introduced stereotaxically into the right lateral ventricle 
(1mm lateral, 0.3mm posterior to the bregma and 2.2mm deep) under deep anaesthesia 
(ketamine/xylazine; ip, 75 and 10mg/kg, respectively), and connected to the mini pump. 
Filled mini pumps were incubated in sterile saline solution at 37°C overnight prior to 
implantation. To facilitate passage of photons emitted by the brain through the skull, a 
depression (diameter 2mm
2
) was made in (but not through) the skull in a region of the left 
frontal cortex (approximate coordinates 2mm lateral to midline, 2mm anterior to bregma), 
in which a glass cylinder (length 4.0mm; diameter 2.0mm
2
) was positioned and fixed with 
dental cement. For peripheral organs, bioluminescence was detected directly through the 
skin in an abdominal region (2.0cm
2
) corresponding to the liver and in a dorsal region 
(1.5cm
2
) corresponding to the left kidney from the same mice. Pelage in these regions was 
removed. 
 For each reading, mice were lightly anesthetized (isoflurane; 2.5% vaporized in O2). 
Bioluminescence was imaged with an ultra-sensitive CCD camera (IVIS 3D; field of view, 10; 
bin factor 2; Xenogen, Alameda, CA, USA). Light emission was integrated over 60s in 
triplicate and these triplicates were averaged yielding one measure per mouse and time 
point. The entire procedure did not last longer than 4min, after which mice were 
immediately returned to their home cage. 
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 Bioluminescence readings from brain and peripheral organs in Per2
Luc
 mice (males and 
females, 3 months of age, brain: n=6/sex; liver and kidney: n=6/sex; total n=24), started 4 
days after introducing the mini pump. Results did not differ with sex (analysis not shown). 
For the time course analyses during baseline, readings were obtained for 8 different times-
of-day (ZT0, -3, -6, -9, -12, -15, -18, and -21) within each mouse spread out over a 4-day 
period such that no more than 2 measures were taken per day spaced at least 12h apart. 
Forty-eight hours after the last baseline reading, the same individuals were used to assess 
the effect of SD. First, control values were acquired the day prior to SD by imaging mice at 
ZT0, -6, -8, and -12. On the SD day (performed from ZT0 to -6) images were taken at ZT6, -8, 
and -12. For the sham, SCNx rhythmic and arrhythmic mice, the same protocol to quantify 
bioluminescence was performed but under complete darkness (DD) conditions. 
 For subsequent analysis, a large region of interest was drawn over the area of light 
emission and photon flux (photons/sec/cm
2
/sr) was measured using Living Image
TM
 
(Xenogen) as an overlay on Igor image analysis software (Wavemetrics, Inc, Lake Oswego, 
OR, USA). All measures were expressed as a percentage of the individual mean 
bioluminescence averaged over the 8 baseline values. With the concentration of D-luciferin 
used here, we found mean photon flux for bioluminescence to be at least 10-times higher 
than background (data not shown), which is consistent with the results described previously 
using the same concentration.
29
 For 3D-reconstruction of bioluminescence source, see 
supplementary methods. 
 Day-to-day stability of bioluminescent signals was assessed in brain, liver, and kidney 
by imaging Per2
Luc
 mice (males, 3 months of age, n=7) daily for 21 days at ZT3 following 
osmotic mini-pump implantation. Signals were found to be stable between days 4 and 10 
after mini pump implantation. This time-window was used for subsequent studies. 
 
Immunohistofluorescence:  Homozygous Per2
Luc
 mice were sacrificed at ZT0, -6, -12, and -18 
and after SD (ZT0-6) at ZT6 (male, 3 months of age, n=3/time point; total n=15). All mice 
were subjected to intracardiac perfusion with PBS-heparin (2 units/ml) and with 4% 
paraformaldehyde in PBS, pH7.4. Brains were carefully removed and post-fixed for 3h at 4°C. 
Brains were cryoprotected in 10% and 20% of sucrose for 1h each and in 30% of sucrose in 
PBS for 48h at 4°C and then embedded in Tissue-Tek O.C.T. compound (VWR International, 
Switzerland) for cryostat sectioning. 
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 ^ĂŐŝƚƚĂůďƌĂŝŶ ƐĞĐƚŝŽŶƐ ;ϯϬʅŵͿǁĞƌĞǁĂƐŚĞĚ ŝŶW^ ;Ϭ͘ϭйdƌŝƚŽŶy-100) and blocked 
(5% goat serum, Sigma Aldrich) and then incubated overnight at 4°C in a humidified chamber 
with primary antibodies directed against mPER2 (1:250; rabbit polyclonal IgG, Alpha 
Diagnostic international, ADi, San Antonio, TX, USA, and rabbit polyclonal IgG, 1:250, Santa 
Cruz, SC-25363, Heidelberg, Germany). The two antibodies yielded similar immunolabeling. 
Primary antibody against Vasopressin (AVP; 1:1000, guinea pig polyclonal anti-(Arg
8
)-
Vasopressin; Peninsula Laboratories, LLC, San Carlos, CA, USA) was used to identify the SCN. 
Sections were incubated at room temperature for 2h with Alexa-488 and Cy3-conjugated 
secondary antibodies [1:1000, Alexa Fluor
®
 488 goat anti-rabbit IgG (Invitrogen) and 1:1000, 
Cy3
® 
polyclonal goat anti-guinea pig IgG (Abcam)]. Finally, sections were incubated with the 
nucleic acid counterstain DAPI (1:1000, room temperature, 5min, Vector laboratories), 
washed, and cover-slipped using Mowiol medium (Polyvinyl alcohol 4-88, Aldrich). Controls 
were performed by omitting primary antibodies, which in all cases resulted in an absence of 
immunofluorescence signal (not shown). 
 Fluorescence from whole brain sagittal views was acquired using a stereomicroscope 
MZ16FA (Leica). All other acquisitions were done with a confocal microscope (Zeiss 510 
LSM). For triple-labeling with two antibodies plus DAPI, the 405-, 488-, and 543nm lines were 
used in alternating acquisition mode. For semi-quantitative analyses of the fluorescence for 
PER2, five sagittal slides per animal (total, n=15 slides) were selected containing the SCN and 
the hippocampus. For each slide, quantification of fluorescence for mPER2 was performed in 
five regions of interest (ROI): cerebral cortex, cerebellum, SCN, and the hippocampal cornu 
ammonis (CA) and dentate gyrus (DG) regions. In each sagittal slide, a ROI (1024 x 1024 
pixels) was defined and a projection of 10 stacks was performed using a confocal microscope 
with the same optical stack distance for all acquisitions. Power of the lasers, opening of the 
pinhole, and detector gain were kept identical for all acquisitions. Z-stacks projections were 
exported in ImageJ 1.33u software to measure the MIP (Maximum Intensity Projection). 
Finally, data were z-transformed prior to statistical analyses. 
 
SCN lesions, locomotor activity, and histology:  Bilateral lesion of the two SCNs was 
performed stereotaxically (Kopf Instruments, 963LS, Miami Lakes, Florida, USA) under 
ketamine/xylazine aneasthesia (intraperitoneal injection, 75- and 10mg/kg, at a volume of 
8ml/kg). Two electrodes (0.3mm in diameter) were introduced bilaterally at the following 
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coordinates (antero-posterior using bregma as reference: +0.5mm, lateral: 0.2mm, depth: 
5.9mm). Electrolytic lesions (1mA, 5sec) were made using a DC lesion device (3500, Ugo 
Basile, Comerio, Italy). Sham mice differed from SCN lesioned mice only in that no electrical 
current was applied. 
 Locomotor activity of Per2
Luc
 mice (age 3-4 months) was recorded under a 12:12h light-
dark conditions (LD12:12, lights on at 09:00, 110lux) at least for 10 days before lesion. After 
lesion, mice stayed 3-4 days under LD12:12, followed by constant dark (DD) conditions for 3 
weeks to verify presence or absence of circadian organization of overt behavior. Activity was 
quantified using passive infra-red (PIR) sensors (Visonic SPY 4/RTE-A, Riverside, CA, USA). 
ClockLab software (Actimetrics, Wilmette, IL, USA) was used for data acquisition and 
analyses. The anatomical site of lesion was verified with Nissl staining on coronal brain 
sections (see Supplementary Figure S5). 
 At the end of the experiments, mice were anaesthetized with ketamine/xylazine 
(intraperitoneal injection, 75- and 10mg/kg, at a volume of 8mL/kg) and perfused 
intracardiacally with PBS-heparin (2units/mL) and with 4% paraformaldehyde in PBS, pH7.4. 
Brains were carefully removed and incubated in 10% and 20% of sucrose for 1h each, and in 
30% of sucrose in PBS for 48h at 4°C, and then embedded in O.C.T. compound (VWR 
International, Switzerland) at -20°C until cryostat sectioning.  
 ŽƌŽŶĂůďƌĂŝŶƐĞĐƚŝŽŶƐ;ϮϬʅŵͿǁĞƌĞǁĂƐŚĞĚŝŶW^ĂŶĚƚŚĞŶpost-fixed in PFA 4% at 
4°C for 10 minutes. Brain sections were then incubated for 10-15 minutes in Cresyl violet 
(Sigma-Aldrich®) and washed in distilled water. Then brain slides were successively 
immerged in ethanol 95%, ethanol 100%, and three xylene baths before to be cover-slipped 
in Eukitt medium (Fluka). Chemical staining from whole brain coronal views was finally 
acquired using a Leica stereomicroscope (MZ16FA) and a Zeiss microscope (LSM510; 
Oberkochen, Germany) with Axiovision software.  
 
Statistics:  Statistical analyses were performed using SAS (SAS Institute Inc, Cary, NC, USA). 
Significant effects of the factors sleep deprivation and time-of-day and their interactions 
were assessed using ANOVA analyses (SAS, procedure GLM) and decomposed using post-hoc 
(paired) t-tests or Tukey’s HSD tests in case more than 2 groups were compared. Statistical 
significance was set to P<0.05 and results are reported as mean r SEM. Circadian rhythmicity 
in locomotor activity was evaluated using chi-square periodogram analysis (P<0.05; Clock 
  9 
lab, Actimetrics, Wilmette, IL, USA). To estimate PER2-bioluminescence rhythmicity in intact, 
sham-lesioned, and SCN lesioned mice, sine waves were individually fit (SAS, procedure 
NLIN) to the 8 data obtained in each organ (liver, kidney, brain) with amplitude and phase as 
free parameters. As an estimate of period, the period length of the individual’s rhythm in 
locomotor activity was used, which for the intact mice under LD12:12 was set to 24.0h. For 
arrhythmic SCN lesioned animals the average period of the sham-lesioned mice was used. 
When the estimated 95% confidence interval for the sine-wave amplitude did not overlap 0, 
bioluminescence was deemed rhythmic. SigmaPlot 11 (Systat Software Inc., Chicago, Il, USA) 
was used for graphs. 
 
 
Results 
The PER2::LUC fusion protein did not appear to interfere with PER2’s clock function judged 
by the intact circadian locomotor activity patterns observed in Per2
Luc 
mice (
27
 and Figure 
S1). Moreover, the baseline amount and distribution of sleep, the response to a 6h sleep 
deprivation (SD), and the sleep-wake driven changes in EEG delta power all indicate that also 
sleep regulation was not affected (Figure S1). 
 Subcutaneous delivery of D-luciferin, the substrate of luciferase, in Per2
Luc 
mice 
resulted in a strong bioluminescence signal throughout the body confirming the ubiquitous 
expression of PER2::LUC and, by inference, PER2 protein in wild-type mice.
27
 Strongest 
bioluminescence signals were observed in two dorsal and one ventral region. Three-
dimensional reconstruction identified the kidney and liver as their respective source (Figure 
S2). Bioluminescence levels were lowest in the head because the skull bone limits photon 
passage. Therefore, in a separate group of mice, the skull was thinned and equipped with a 
glass cylinder to assess brain PER2-bioluminescense (Figure 1A). Stable bioluminescence 
levels in brain, liver, and kidney were reached by day 4 after the start of luciferin delivery 
and maintained until day 10 (Figure S2). All subsequent experiments were performed within 
this 7-day window following the protocol illustrated in Figure S3. 
 
In vivo assessment of the effects of time-of-day and sleep deprivation on PER2 protein 
under entrained conditions 
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The in vivo, nychthemeral changes in PER2 protein levels were quantified in brain, liver, and 
kidney. Robust, 3-fold changes in PER2 were observed in all three tissues with a nadir 
reached in the middle of the light-period (ZT6), while maximal levels were reached 3h after 
dark onset (ZT15) in the kidney and 3h before light onset (ZT21) in the liver and brain (Figure 
1B). These changes in PER2 bioluminescence were similar in phase and amplitude to the 
changes obtained by western-blot analyses in a small subset of mice (Figure S4). This 
indicates that turnover of the PER2::LUC fusion protein and of the native PER2 protein are 
regulated in similar fashion and can be reliably monitored by bioluminescence in vivo. 
 We have previously shown that enforced wakefulness (i.e., sleep deprivation) 
increases Per2 mRNA levels in the brain
8,10,15-18
 suggesting that the nychthemeral sleep-wake 
distribution contributes to the nychthemeral (and circadian) changes in PER2 protein levels 
described here and previously by others.
30
 The resemblance among the baseline time 
courses of locomotor activity, wakefulness, and PER2 levels, particularly in the brain, already 
support this (Figures 1 and S2). To further investigate this relationship, mice were sleep 
deprived (SD) for 6h (ZT0-6). Sleep deprivation was followed by an increase in PER2 levels 
not only in the brain, but also in liver and kidney, although the dynamics of this change 
during recovery sleep greatly varied among the three tissues (Figure 1C). In the brain, SD 
greatly attenuated the pronounced decrease in PER2 observed during corresponding 
baseline hours and 1.8-fold higher PER2 levels were observed immediately after SD, 
consistent with the about 2-fold increase in Per2 mRNA levels observed after SDs performed 
at this time of day.
8,10,15-18
 Brain PER2 levels were still increased after 2h of recovery sleep 
(ZT8) before reverting to baseline over the 4 subsequent recovery hours (Figure 1). Sleep 
deprivations as short as 3h are sufficient to increase Per2 mRNA.
15
 In a separate group of 
mice, we confirmed that 3h also suffices to fully counter the profound decrease in PER2 
occurring between ZT0-3 (blue data point in the Figure 1B), suggesting that the sleep-wake 
driven changes in PER2 translation closely follow the changes in mRNA contrasting the long 
time-lag between the two reported for their circadian dynamics.
21,31
 
 Surprisingly and in stark contrast to the PER2 dynamics in the brain, liver levels 
remained elevated above baseline for the entire 6h over which recovery was measured 
while in kidney, a significant increase was observed at ZT8 only; i.e., after 2h of recovery 
sleep. Western-blot analysis of liver confirmed these bioluminescence results including the 
prolonged increase in PER2 after SD (Figure S4). 
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Brain topography of the PER2 increase after sleep deprivation 
We then determined which brain areas contributed to the SD-induced changes in brain PER2 
bioluminescence using immunohistofluorescence. Sleep deprivation increased PER2 
fluorescence in the cerebral cortex, especially in the cingulate and motor cortices, the 
olfactory bulb, and cerebellum (Figure 2A). Close inspection of the brain areas directly under 
the site at which bioluminescence was sampled in vivo (see Methods); i.e., the cerebral 
cortex and the hippocampal fields CA1-3 and dentate gyrus, revealed that PER2 positive cells 
in cortical layers IV and V showed stronger fluorescence after SD as compared to baseline 
(Figures 2B and 3B; quantified in Figure 3G). Both the cell nuclei (co-localization with DAPI) 
and cytoplasm of these cells stained positive for PER2, with no apparent labeling of axonal 
projections (Figures 2B and 3B). PER2 positive cells were also found in the pyramidal cell 
layer throughout the CA fields of the hippocampus (Figures 2E and 3E). The cytoplasm, 
nucleus, and axonal projections of these cells stained all positive for PER2 (Figure 3E). PER2 
staining was also observed in the granular cell layer and hile of the dentate gyrus (Figures 2F 
and 3F). Sleep deprivation did, however, not significantly modify PER2 staining in these 
hippocampal areas (Figures 2E and 2F; quantified in Figure 3G). It thus seems that the 
specific increase in PER2 expression in the cerebral cortex underlies the increase in 
bioluminescence observed in the brain in vivo. 
 Sleep deprivation increased PER2 also in the cerebellum (Figures 2A and 2D) although 
this increase failed to reach significance levels when quantified in the defined region of 
interest (Figure 3G). Visually identified Purkinje cells displayed a particularly strong PER2 
fluorescence signal in the cytoplasm and axonal projections while in the nucleus PER2 was 
conspicuously absent (Figure 3D), contrasting the observations made in cerebral cortex and 
hippocampus. This absence of nuclear PER2 was noticed also at the other 3 times-of-day 
(data not shown). 
 Because SD can alter the phase of circadian activity rhythms
32
 and affects multi-unit 
activity in the SCN
33
, SD-dependent changes in PER2 in the SCN were anticipated. At the 
sagittal plane depicted (0.10-0.15mm lateral to midline), the SCN can be clearly discerned by 
the denser DAPI staining and the presence of vasopressin (AVP), which is specific of the 
dorso-medial region of the SCN (in red; Figures 2A and 2C). Most SCN cells positive for PER2 
also stained for AVP but PER2 was clearly expressed in both the nucleus and cytoplasm, 
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whereas AVP is mainly cytoplasmic (Figure 3C). At the end of the SD (ZT6), only few PER2-
positive cells were observed in the SCN and PER2 fluorescence after SD did not differ from 
that observed during baseline (Figures 2C and 3G). The lack of an effect of SD on PER2 levels 
in the SCN, along with decreased neuronal activity in the SCN,
33
 could point to a dissociation 
of the molecular circadian clock from its neuronal output. 
 We then followed the changes in brain topography of PER2 expression over the day. In 
general, expression was highest and most wide-spread at ZT18 and lowest at ZT6 (Figure 3A). 
Nevertheless, quantification of these expression profiles showed that changes in 
fluorescence differed across the five areas for which it was quantified. No statistical variation 
in PER2 levels were observed in the dentate gyrus contrasting the large, 4.7-fold peak-to-
trough changes observed in the SCN with maximal levels reached at ZT12 and minimal values 
at ZT0 (Figures 3C and 3G). Timing of peak and trough values varied among the other 
structures quantified (cerebellum: ZT18 and -12; CA: ZT0 and -12; cerebral cortex: ZT18 and -
6, respectively). Of these profiles, the time-course of PER2 fluorescence in the cerebral 
cortex matched the changes of brain bioluminescence in Per2
Luc
 mice best (Figure 1B), again 
underscoring that the bioluminescence signal we quantified originated there. 
 Because the time-spent-awake and -asleep varies as a function of time-of-day and 
because enforced waking increases PER2 in the brain, the baseline sleep-wake distribution is 
likely to have contributed to these nycthemeral changes in PER2 expression. We therefore 
compared the SD-induced regional changes in PER2 expression to those observed after an 
extended period of spontaneous wakefulness like is the case at ZT18. High PER2 levels were 
observed both after SD and at ZT18 in the cerebral cortex, the cerebellum, and olfactory 
bulb (Figures 2A and 3A) and the levels quantified in the cortical and cerebellar regions 
(Figure 3G) indicated that spontaneous and enforced waking similarly contributed to the 
high PER2 levels in these areas. Despite these similarities between enforced and 
spontaneous periods of wakefulness with respect to PER2 levels, the important and 
widespread PER2 expression observed at ZT18, especially noticeable in the mid-brain and 
pontine areas, was conspicuously absent at ZT6 after the SD. Finally, PER2 in the SCN did not 
seem to be affected by sleep-wake states as highest levels were reached after the main rest 
phase and decreased over the main active period (Figures 3C and 3G), consistent with the 
fact that SD does not affect PER2 levels in this structure. 
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In vivo PER2 assessment in SCN-lesioned Per2
Luc
 mice under constant-dark conditions 
Next we studied the relationship between wakefulness and PER2 levels under constant dark 
(DD) conditions when circadian rhythms free-run. We also assessed the effects of lesioning 
the SCN (SCNx) (or the lack of circadian rhythms in locomotor activity), on PER2. Under DD 
conditions all Per2
Luc 
sham-operated mice displayed robust, circadian locomotor activity 
patterns resembling those observed in intact mice (Figures 4B and S5). Of the SCNx mice 
53% still displayed significant rhythmicity albeit less robust statistically, likely due to 
incomplete lesioning of the SCN (for ʖ2-analysis and histology see Figure S5). Average free-
running periods did not differ between sham and rhythmic SCNx (rhySCNx) mice (24.2 ± 0.1h 
and 24.0 ± 0.1h, respectively). Compared to the LD12:12 condition, under DD the active 
period (alpha) expanded in both sham and partial lesioned mice (12.0 ± 0.1h vs. 14.8 ± 0.3h 
and 14.9 ± 0.4h, respectively; 1-way ANOVA p<0.0001; LD < sham = rhySCNx; post-hoc 
Tukey, p<0.05) increasing the time between the first main activity bout defining activity 
onset and the second main activity bout preceding rest onset. As a result, the bi-modal 
distribution of locomotor activity, already noticeable under LD12:12 (Figure 1D), became 
more pronounced especially in rhythmic SCNx mice (Figure 4B). In the arrhythmic SCNx mice 
no circadian organization of locomotor activity was detected and histological analyses did 
not reveal any remaining SCN tissue (Figure S5). 
 Following the same protocol used for the LD12:12 experiments (Figure S3), in vivo 
changes in PER2 bioluminescence were quantified over the circadian day in brain, liver, and 
kidney under DD conditions. For sham and rhythmic SCNx mice, average circadian PER2 
profiles were constructed using individual period and phase information from the locomotor 
activity rhythms with circadian time 12 (CT12) as activity onset. In sham mice clear 
circadian PER2 patterns were readily discerned which paralleled activity patterns in similar 
fashion as under LD12:12 (Figure 4A, see Figure 1B for comparison). This included the 
bimodality in activity observed under DD, as also PER2 bioluminescence profiles showed two 
peaks in the active period, especially clear in kidney. Timing of the peak in the active phase, 
and the trough in the rest phase, were also similar as under LD12:12 while peak-trough 
amplitudes were somewhat smaller under DD conditions (2.4-, 2.2-, 1.9-fold for brain, liver, 
and kidney, respectively vs. 3.0-fold under LD12:12). Also in rhythmic SCNx mice, we 
observed circadian changes in PER2 similar to sham mice in all three organs but again with a 
smaller fold-change [1.9-, 1.7-, and 1.7-fold in brain, liver, and kidney, respectively; 2-way 
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ANOVA on the peak-trough amplitudes with factors ‘Group’ (LD, sham, rhySCNx; P=0.0015) 
and ‘Tissue’ (brain, liver, kidney; p=0.0031); interaction p=0.83; post-hoc Tukey; Group: LD > 
rhySCNx; Tissue: Brain > Kidney; p<0.05]. Also the analyses of the amplitude of sine-wave 
functions fitted to the changes in PER2 confirmed that amplitude decreases from intact mice 
under LD12:12 to sham mice under DD, to rhythmic SCNx mice under DD (Table 1). 
 In arrhythmic SCNx (arrSCNx) mice, no apparent circadian rhythm in PER2 
bioluminescence was present in any of the three tissues (Figure 4A). However, since no 
activity rhythms were present, time courses of individual mice could not be aligned in a 
meaningful manner and we resorted to constructing average temporal PER2 profiles using 
average activity onset and period length of the rhythms observed in the sham-operated mice 
recorded in parallel. To address this limitation, we analyzed rhythmicity in all individual mice 
of the four experimental groups (LD, sham, rhySCNx, and arrSCNx) using a simple sine-wave 
fitting procedure (see Methods and Table 1 for details). Due to the sparsity of data (only 
eight samples covering one cycle per tissue and mouse) and due to the strong bimodality in 
PER2 that precluded fitting a sine function in some individuals, significant rhythms were not 
always obtained although clear rhythms being present visually. Despite these shortcomings, 
this method confirmed that under LD12:12 all tissues of all mice displayed PER2 rhythms to 
which a sine wave with an amplitude significantly deviating from zero could be fitted (Table 
1). In the arrhythmic SCNx group, none of the liver recordings met this criterion while in 
brain and kidney PER2 changes were still deemed rhythmic in 14 (1/7) and 40% (2/5) of the 
mice, respectively. 
 
Effects of DD and SCNx on the sleep-deprivation induced increase in PER2 
In a final experiment we repeated the sleep deprivation under constant dark conditions to 
rule out eventual effects of light and entrainment. Moreover, we assessed whether an intact 
SCN (or a circadian organization of sleep-wake behavior) is required for the effects of sleep 
loss on PER2 expression. Consistent with the SD experiment under LD12:12, the 6h SD was 
scheduled from CT0-6. Since the active period expanded by almost 3 (circadian) hours under 
DD compared to LD12:12 (see above), the start of the SD no longer coincided with the onset 
of the rest phase. Nevertheless, under both DD and LD12:12 conditions the SD took place 
during the time PER2 levels steeply declined and both resulted in very similar, tissue-specific 
recovery dynamics (Figure 5 vs. Figure 1B). In sham-operated mice PER2 levels reached at 
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the end of the SD were again largest in brain of the sham mice after which they reverted to 
baseline levels over the following 6h. In kidney, changes were largest at CT8, and in liver 
PER2 remained elevated for the entire 6h recovery period as under LD12:12. 
 In rhythmic SCNx mice, PER2’s response was very similar albeit less pronounced (Figure 
5). This reduced response to SD was not due to differences in the PER2 values reached 
during recovery as they did not differ for any of the three time points and tissues among the 
three groups [2-way ANOVA with factors ‘group’ (sham, rhySCNx, arrSCNx), time (CT6, -8, 
and -12) for SD condition: ‘group’ p=0.60, 0.29, and 0.08 for brain, liver, and kidney, 
respectively]. Instead, this reduced relative increase was due to the fact that in rhythmic 
SCNx mice the PER2 values during baseline did not drop to the low values reached in sham 
mice [ANOVA for baseline condition: ‘group’ p=0.02, 0.01, and 0.005, for brain, liver, and 
kidney, respectively; post-hoc Tukey, p<0.05; CT0: brain and kidney: sham = rhySCNx > 
arrSCNx; liver: sham > arrSCNx; CT6: brain: arrSCNx > rhySCNx = sham; CT8: kidney: arrSCNx 
> rhySCNx = sham; liver: arrSCNx = rhySCNx > sham; CT12: kidney: rhySCNx > sham]. In 
arrhythmic SCNx mice, this baseline decrease in PER2 did not occur and during recovery 
from SD only modest effects were observed (Figure 5). Nevertheless, significant increases 
were also observed in this group, especially in the liver where after 2- and 4h of recovery 
PER2 levels were still increased over basal levels. 
 
 
Discussion 
In circadian research, live imaging of reporter genes has been widely used (e.g.
34,35
) and 
contributed to the rapid progress in that field. In animals these techniques were applied first 
in vitro and ex vivo in cells and tissues (e.g.
27,36,37
), and more recently, in vivo in the whole 
living organism.
29,38-40
 In these in vivo studies circadian changes in bioluminescence could be 
followed in specific tissues of interest such as SCN, olfactory bulb, liver, and kidney. Because 
the same animal can be repeatedly sampled, these imaging techniques have an important 
advantage over more conventional techniques to quantify protein in that only a fraction of 
animals are needed to construct a circadian time course, and between-subject differences 
can be taken into account, thereby improving data quality. With the protocol we established, 
highly stable levels of bioluminescence could be maintained for the seven days without 
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further intervention. Variability in relative bioluminescence among individuals was small 
with a coefficient of variation typically around 20% for any given time point. 
 In the sleep field, in vivo measurement of protein expression in the intact animal has 
not yet been widely applied. We here report on the central and peripheral effects of sleep 
deprivation on PER2 protein levels under standard light-dark conditions and under constant 
dark conditions both in intact and SCN-lesioned mice. We discovered that similarly to mRNA, 
PER2 protein in the brain quickly increases with sleep deprivation and that this increase 
concerns the cerebral cortex mainly. These results further add to the notion that clock genes 
not only play a role in circadian rhythm generation but also in the homeostatic regulation of 
sleep.
2
 Moreover, we found that sleep deprivation not only targets the brain but also 
peripheral tissues. Finally, we investigated the consequences of a SCN lesion on circadian- 
and wake-dependent changes in PER2. In three mice, significant PER2 circadian rhythmicity 
could still be detected in brain and kidney while rhythms in locomotor activity were lacking. 
Against expectation, sleep deprivation in arrhythmic SCNx mice resulted only in a modest 
relative increase in PER2 expression, mostly in liver, due to the higher baseline PER2 levels in 
this experimental group. 
 
Comparing the effects of sleep deprivation on Per2 mRNA and protein levels 
The wake-dependent increase in Per2 expression has been documented in a number of 
studies under a variety of experimental conditions demonstrating that both circadian and 
activity-induced contributions have to be considered when analyzing Per2’s time course.
18
 If 
Per2 is to play a functional role in sleep homeostasis, also its protein product should increase 
within the time frame known to activate a homeostatic response in sleep. From circadian 
time course analyses in; e.g., the SCN, it is known, however, that a long, 6- to 8h lag exists 
between the time at which Per2 mRNA and PER2 protein peak.
19
 Comparing our previous 
mRNA work with our current protein results, we confirmed the existence of such long time 
lag also in the brain; whereas mRNA started to decrease at ZT18,
18
 the marked decrease in 
PER2 started 6h later; i.e., at ZT0 (or CT0 under constant dark conditions). In our study, 
higher than baseline levels of PER2 were already observed after a 3h sleep deprivation 
similarly to Per2 mRNA,
15
 suggesting that PER2 protein closely follows mRNA changes when 
activated through non-circadian pathways. Similarly, light-induced increases in PER2 protein 
in the SCN occurs within 4h
41,42
 and corticosterone-induced increases in PER2 in specific 
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brain areas have been reported to occur within 1h.
43
 These findings underscore that Per2 
has immediate-early gene properties when activated through non-circadian signaling 
pathways, which modulate and are modulated by the ongoing circadian rhythm in PER2. We 
have previously quantified and successfully mathematically modeled this non-linear 
interaction between circadian and activity-induced factors that determine Per2 mRNA 
levels.
18
 Based on the limited available data, the recovery dynamics of mRNA and protein 
seem to be less tightly coupled; whereas after 2h of recovery sleep Per2 mRNA levels did 
already revert to baseline, for PER2 protein baseline levels were attained 4h later. 
 
Sleep loss increases PER2 in the cerebral cortex 
Within the brain the cerebral cortex, especially its layers IV and V, was most responsive to 
sleep loss in terms of the changes in PER2 levels. Given PER2’s immediate-early gene 
properties (see above), increased expression in these two cortical layers could reflect 
increased sensory input (layer IV) and motor output (layer V)
44
 associated with the sleep 
deprivation protocol. In contrast to the prominent changes observed in the cortex, sleep 
deprivation did not affect PER2 levels in the SCN. At the mRNA level similar dissociations 
between Per2 expression rhythms in cortex and SCN have been observed under conditions 
of food restriction, spontaneous splitting, and methamphetamine administration where, 
invariably, expression in the cortex follows behavior (locomotor activity), while in the SCN its 
rhythm remains unperturbed and entrained to the light-dark cycle.
45-48
 Functionally this 
makes intuitive sense as the SCN is required for time keeping and should therefore be 
shielded from the influence of the behaviors it drives. In contrast, we previously argued that 
in forebrain areas circadian clock genes are necessary to adapt to and anticipate 
homeostatic challenges such as food restriction and sleep deprivation.
10,30,49,50
 The 
predominant effects of sleep deprivation on PER2 in the cerebral cortex is consistent with 
the many cortical related functions and activities that are affected by acute sleep 
deprivations, including increases in EEG slow waves, cognitive performance, and energy 
metabolism.
51
 
 In the cerebral cortex, similar levels of PER2 protein were reached immediately after 
enforced and spontaneous periods of wakefulness underscoring that at least a part of the 
variation in PER2 are secondary to the distribution of sleep and wakefulness and not 
primarily circadian driven. It is important to note that while animals are awake during sleep 
  18 
deprivation, they will immediately revert to sleep when not stimulated, especially toward 
the end of the sleep deprivation. In contrast, during spontaneous waking, ‘stimulation’ can 
be said to be endogenous. The important and widespread PER2 expression observed at 
ZT18, especially clear in the mid-brain and pontine areas was conspicuously absent after the 
SD at ZT6. These areas contain several structures known to play important roles in the 
promotion of wakefulness and in sustained attention.
52
 Thus, sleep deprivations performed 
during the rest phase, while activating the cerebral cortex, leave the rest of the brain 
molecularly asleep based on the PER2 levels measured here. These areas could be involved 
in mediating circadian wake-promotion that we observed at this time of day.
18
 
 Apart from the SCN, the most important nychthemeral changes in PER2 were observed 
in the cerebral cortex and cerebellum whereas no rhythmic expression was found in the 
hippocampus confirming previous studies and suggesting different physiological roles for 
PER2 in these brain regions.
53-55
 Also the subcellular localization of PER2 differs among the 
brain regions evaluated here. In cortex and the SCN, neuronal PER2 is mainly nuclear and 
expressed in the perikaryon. In stark contrast, in cerebellar Purkinje neurons, PER2 is mainly 
cytoplasmic and expressed in projections but lacking from the nucleus as has been shown in 
one other study.
56
 The absence of PER2 in the nucleus was observed at all times of day and is 
particularly surprising because, as a core circadian transcriptional regulator, PER2’s nuclear 
presence is essential,
21
 and because the strong PER2 rhythms observed in Purkinje neurons 
are functionally important in circadian food anticipatory behavior.
55
 Whether in Purkinje 
cells other CLOCK::BMAL1 and CLOCK::NPAS2 repressors, such as PER1, are expressed in the 
nucleus and thus could substitute for the absence of PER2, is unknown. 
 
The effects of sleep loss on PER2 in SCNx mice 
Sleep deprivation performed between ZT0 and -6 (or CT0 and -6), efficiently countered the 
marked decrease in PER2 occurring at this circadian phase resulting in higher than baseline 
levels both centrally and peripherally. However, in the absence of this baseline decrease, 
such as in the arrhythmic SCNx mice, sleep deprivation did not appreciatively elevate PER2 
above background in brain and kidney. We have previously shown, at the mRNA level in the 
brain, that although sleep deprivation generally resulted in levels of Per2 expression above 
baseline, these increases were strongly modified by the time of day the sleep deprivation 
was performed such that mRNA even decreased from their initial levels for sleep 
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deprivations scheduled between ZT18 and -24.
18
 How this interaction between time-of-day 
and sleep deprivation at the mRNA levels translates into changes in PER2 protein levels is 
difficult to predict as the temporal relationship between the two seems to differ for 
circadian and induced aspects of Per2–PER2 regulation (see above). Further complicating the 
interpretation of the sleep deprivation results obtained in arrhythmic SCNx mice is the fact 
that in the absence of a behavioral phase marker, the timing of the sleep deprivation was 
determined by that of the sham operated mice. Inspection of the few behaviorally 
arrhythmic SCNx mice that still showed evidence of circadian rhythmicity in PER2 levels 
revealed that sleep deprivation was not always performed at the time PER2 decreases as 
was done for the other experimental groups (data not shown). Whether intact circadian 
rhythms are a requirement for the sleep-deprivation induced increase in PER2 in the brain 
can therefore not be conclusively answered here. Future experiments using a recently 
developed imaging technique for the long-term online monitoring of PER2 bioluminescence 
in freely behaving mice
40
 would enable using the phase of the PER2 rhythm itself (if present), 
rather than relying on the phase of the activity rhythms to schedule the sleep deprivation. 
Nevertheless, sleep deprivation did significantly increase PER2 in livers of arrhythmic SCNx 
mice with dynamics similar to those observed in the other experimental groups 
demonstrating that at least in this tissue the effects of sleep-deprivation do not depend on a 
functional circadian clock. 
 Notwithstanding the limitations of our analysis already mentioned in the results 
section, we did identify three mice in which circadian rhythms in PER2 were detected while 
rhythms in locomotor activity were absent after lesioning the SCN. Thus although the SCN is 
needed for circadian rhythms in overt behaviors, in peripheral organs (including brain areas 
outside the SCN) molecular circadian rhythms can still be maintained in some cases, 
consistent with the ex vivo experiments performed by Yoo and colleagues
27
 and the in vivo 
experiments by us and others
39,40
 (but contrasting the work of Guo and colleagues
57
). 
Importantly, in the two previous studies that did observe circadian PER2 expression in kidney 
and liver in some of the arrhythmic SCNx mice, it was noted that the amplitudes of the 
changes in PER2 were reduced. Thus in the intact animal circadian driven behaviors, such as 
the circadian sleep-wake distribution and the resulting rhythms in e.g. feeding, temperature, 
metabolism, and clock genes,
2,58,59
 contribute to amplify these locally generated rhythms. 
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Conclusion 
Functionally sleep has and still is generally seen as a state needed to ensure proper brain 
functioning.
51,60,61
 It has become clear, however, that sleep loss has immediate adverse 
consequences on e.g. metabolic balance and immune function (e.g.
62,63
). Accumulating 
evidence from molecular studies support that altered timing of sleep and sleep loss greatly 
impact gene expression in the periphery both in mice and humans.
16,24-26
 While we see an 
immediate and profound increase in PER2 in the brain, the effects in liver were longer lasting 
and preserved in SCNx mice. The liver expression of Per2 was found to be rhythmic in mice in 
which the clock circuitry was arrested specifically in liver,
64
 demonstrating that rhythms in 
Per2 expression can be driven by both systemic cues and peripheral oscillators. In light of our 
current results the sleep-wake distribution is likely to be one of these systemic cues. Chronic 
disruption of sleep also affects the peripheral expression of clock genes, including that of 
Per2, in humans.
26
 Although chronic sleep loss and disrupted circadian rhythmicity both 
negatively impact energy metabolism,
62,65-67
 whether the same or different pathways are 
implicated is, however, unknown. Based on our findings that the sleep-wake distribution 
alters PER2 levels in the periphery, it is tempting to speculate that some of the adverse 
peripheral effects of sleep loss are mediated through its effects on clock genes. 
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Table and Figure legends 
 
Tissue 
 
LD 
condition 
SCN / 
behavioral 
status 
 
% rhythmic 
PER2 biolum 
 
Sine-wave 
amplitude [%]  
 
ANOVA 
‘Time’ [P] 
 
n 
Brain LD12:12 Intact 100 49.8 (5.3) <0.0001 13 
DD Sham 67 40.7 (4.9) <0.0001 6 
SCNx / rhy 33 22.7 (5.5) 0.0011 6 
SCNx / arr 14 17.0 (2.0) 0.0016 7 
Liver LD12:12 Intact 100 44.3 (3.7) <0.0001 12 
DD Sham 86 36.5 (4.7) <0.0001 7 
SCNx / rhy 75 33.8 (4.4) <0.0001 8 
SCNx /arr 0 15.9 (1.3) 0.21 5 
Kidney LD12:12 Intact 100 45.1 (2.7) <0.0001 12 
DD Sham 57 23.6 (4.6) <0.0001 7 
SCNx / rhy 13 17.1 (2.5) <0.0001 8 
SCNx / arr 40 12.7 (3.1) 0.42 5 
 
Table 1: Parameter estimates of PER2 rhythmicity. Rhythmicity of PER2-bioluminescence was 
assessed by fitting a sine function to the 8 data points measured 3h apart within individual mice with 
phase and amplitude as free parameters (SAS, proc NLIN). Under light-dark (LD12:12) conditions 
period was set to 24.0h, while under constant dark (DD) conditions the individual’s free-running 
period of locomotor activity during the recording period was used. Because period length cannot be 
determined in arrhythmic mice, the mean value of the sham-lesioned mice was used. Individual time 
courses were deemed rhythmic when the 95% confidence interval estimated for the amplitude of the 
fitted sine-wave did not cross zero. Note that a sine function could not always be reliably fitted 
despite clear rhythms in PER2-bioluminescence being present. This was more often the case in the 
brain where bi-modality of the signal was observed (see Figures 1 and 4). In all tissues the fitted 
amplitude (including those estimated in mice deemed not rhythmic) was largest in Intact mice under 
LD12:12 [2-way ANOVA factors ‘Group’ (Intact, Sham, SCNx/rhy, SCNx/arrhy): P<0.0001 and ‘Tissue’ 
(Brain, Liver, Kidney): P=0.015; interaction: P=0.28; Brain: Intact > SCNx/rhy, SCNx/arrhy; Sham > 
SCNx/arrhy; Liver: SCNx/arrhy < Intact, Sham, SCNx/rhy; Kidney: Intact > Sham, SCNx/rhy, 
SCNx/arrhy; post-hoc Tukey, P<0.05). Finally, ANOVA analyses revealed that in all 3 tissues of the 
Intact, Sham, and SCNx/rhythmic groups the effects of factor ‘Time’ was significant, while in the 
SCNx/arrhythmic group only in the brain a significant time effect was observed. Note that this 
ANOVA analyses does not test for the presence of circadian rhythmicity and that in the 
SCNx/arrhythmic group the time course of bioluminescence could not be objectively aligned among 
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individuals because phase-markers of circadian rhythmicity were lacking. For this group, phase and 
period to align data were taken from the Sham group averages that were recorded in parallel. 
 
Figure 1:  Time-of-day and sleep deprivation affect PER2 protein levels under light-dark conditions.  
A: An example of the daily changes (ZT0-24; 3h intervals) in bioluminescence (color coded as ‘heat’ 
scores) emanating from the left frontal cerebral cortex through a glass cylinder (red arrow in left 
panel) of an individual of Per2
Luc
 mice. Bioluminescence images are superimposed on photos of the 
mouse’s head. Luciferin was delivered through a cannula (yellow arrow) into the right lateral 
ventricle. Strongest signals (red color) were observed at ZT21 and ZT0/24. B: Mean (±1 SEM) 
bioluminescence levels in brain, liver, and kidney (n=12) under baseline conditions (ZT0-24; 3h 
intervals; grey line) and at ZT6, -8, and -12 (black line) after a 6h sleep deprivation (SD; ZT0-6; dashed 
line). Values were expressed as % of the individual mean bioluminescence in baseline before 
averaging. Horizontal dashed lines indicate mean bioluminescence (i.e., 100%). Blue data point 
indicates mean (±1 SEM) bioluminescence at ZT3 after a 3h SD (n=3). C: Mean fold-change in 
bioluminescence (vertical bars, +1 SE of the ratio) in brain (black), liver (brown), and kidney (green 
bars) at 0-, 2-, and 6h of recovery after SD (i.e., ZT6, -8, and -12) compared to corresponding baseline 
measures within individuals. Red triangles mark significant deviations from baseline (post-hoc paired 
t-tests; P<0.05). The initial increase after SD, at ZT6, is larger in brain compared to kidney (red 
asterisk; post-hoc Tukey; P<0.05). D: Time course of mean locomotor activity. Hourly values were 
expressed as % of the mean individual 24h activity before averaging. Horizontal line indicates mean 
activity (i.e., 100%). Grey areas in panels B and D delineate the 12h dark periods.  
 
Figure 2:  Brain immunohistofluorescence of PER2 after a 6h sleep deprivation.  A: Representative 
examples of sagittal brain sections of Per2
Luc
 mice showing PER2 expression (green pseudocolor) at 
ZT6 under baseline conditions (CTRL) and after a 6h sleep deprivation (SD; ZT0-6). In addition, 
sections were stained for AVP (red), to mark the SCN, and DAPI (blue), to visualize cell nuclei. White 
boxed areas mark the five brain regions detailed in Panels B-E; i.e., cerebral cortex (B), SCN (C), 
cerebellum (D), and the hippocampal areas Cornu Ammonis (CA; E) and dendate gyrus (DG, F). 
Roman numerals in panel B indicate cortical layers I-VI with tick marks estimating layer boundaries 
based on visual inspection of cyto-architectural variation in each section. Scale bar in panel A is 
ϭϮϱϬʅŵĂŶĚŝŶƉĂŶĞůƐ-&ϱϬʅŵ͘ 
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Figure 3:  Brain immunohistofluorescence of PER2 as a function of time-of-day.  A: Sagittal brain 
sections of Per2
Luc
 mice showing PER2 levels (green) co-stained with an AVP antibody (red; lower 4 
panels) at ZT0, -6, -12, and -18. Note the red AVP staining in the SCN (box C) turning yellow when 
PER2 is high (ZT12 and -18). The same sections were counterstained for DAPI (blue; upper 4 panels). 
Detailed PER2 staining is shown for cerebral cortex (B), SCN (C), cerebellum (D), and the Cornu 
Ammonis (CA) (E) and dendate gyrus (DG, F). Details for SCN (C), cerebellum (D), and CA (E) shown at 
higher magnification at times of high PER2 expression (i.e., ZT12, -18, and -18, respectively). Note 
that 1) many PER2 positive cells can be seen in cortical layers IV and V, 2) most PER2 positive cells 
(green) in the SCN also express AVP (red; yellow when overlain), 3) the cytoplasm and axons but not 
the nuclei of Purkinje neurons in the cerebellum express PER2 (see white arrows), and 4) many cells 
in the hippocampus, specifically in the granule cell layer and subgranular zone, are PER2 positive. G: 
Quantification of PER2 fluorescence for the five brain regions at ZT0 (double plotted at ZT24), -6, -12, 
and -18 (gray line) and at ZT6 after a 6h sleep deprivation (SD; ZT0-6; black line; see data in Figure 2). 
Numbers besides data points indicate other ZT times from which the data point significantly differed 
(post-hoc Tukey; P<0.05). Note that SD significantly changed PER2 levels only in the cerebral cortex 
(red asterisk; post-hoc t-test; P<0.05). Grey areas mark the 12h dark periods. Scale bar in panel A is 
ϭϮϱϬʅŵ͕ŝŶƉĂŶĞůƐ-ĂŶĚŝŶĚĞƚĂŝůƐϱϬʅŵ͘^ĞĞ&ŝŐure 2 for details. 
 
Figure 4:  PER2 bioluminescence levels as a function of circadian time in sham operated mice and in 
rhythmic and arrhythmic SCN-lesioned mice under constant dark conditions. A: Mean (±1 SEM) 
bioluminescence levels in brain, liver, and kidney under baseline conditions (CT0-24; 3h intervals; 
grey line; for n/group/tissue see Table 1). Values were expressed as percentage of individual mean 
bioluminescence in baseline before averaging. CT within individuals was calculated according the 
individual’s free-running period using activity onset as CT12 for the sham and SCNx/rhythmic Per2
Luc
 
mice (see Panel B). For SCNx/arrhythmic mice mean period and activity onset of the sham group 
were used to construct an average time course. B: Mean circadian locomotor activity waveforms for 
sham lesioned and SCNx-rhythmic and -arrhythmic mice. Activity values were expressed as a 
percentage of each individual’s mean activity. Note the two peaks in the activity for Sham and SCNx/ 
rhythmic mice. Grey and white areas delineate the subjective dark or active ;ɲͿĂŶĚůŝŐŚƚor rest ;ʌͿ
periods, respectively. 
 
Figure 5:  PER2 levels after sleep deprivation in sham operated mice and in rhythmic and 
arrhythmic SCN-lesioned mice under constant dark conditions. A. Mean (±1 SEM) bioluminescence 
levels in brain, liver, and kidney under baseline conditions (CT0, -6, -8, and -12; grey line), and after 0-
, 2-, and 6h of recovery sleep following a 6h sleep deprivation (SD CT0-6, dashed line, black line; 
  24 
brain: n=3, 4, and 4; liver and kidney: n=3, 3, and 5 for sham, SCNx-rhythmic, and -arrhythmic mice, 
respectively). PER2 values were expressed as a percentage of the individual mean bioluminescence in 
baseline. As the 4 baseline measurements obtained in these mice did not span an entire cycle direct 
comparisons to the relative values depicted in Figures 1 and 4 could not be made. To accommodate 
this we linearly adjusted the average values obtained here to the 4 corresponding mean relative 
baseline values depicted in Figure ϰ͘'ƌĞǇĂƌĞĂƐĚĞůŝŶĞĂƚĞƐƵďũĞĐƚŝǀĞĚĂƌŬƉĞƌŝŽĚƐ͖ ŝ͘Ğ͕͘ɲ͘B. Mean 
fold-change in bioluminescence (vertical bars, +1 SE of the ratio) in brain (black), liver (brown), and 
kidney (green bars) after 6h SD compared to their own corresponding baseline. Red triangles mark 
significant deviations from baseline (post-hoc paired t-tests; P<0.05). 
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Supplemental Information  
“In vivo imaging of the central and peripheral effects of sleep deprivation and SCN lesion on 
PERIOD-2 protein in mice” by Curie, Maret, Emmenegger, and Franken 
 
 
1. Inventory of Supplemental Information 
As supplemental information we provide three experimental procedures, concerning the EEG 
recordings, Western-blot analyses, and 3D bioluminescence reconstruction, respectively, and 5 
figures: Figure S1 shows sleep EEG recordings in Per2Luc mice under baseline and sleep deprivation 
conditions. Figure S2 illustrates the 3D reconstruction of bioluminescence source localization of 
peripheral PER2 protein. Figure S3 illustrates the protocol used to sample bioluminescence in 
living Per2Luc mice and locomotor activity data demonstrating that circadian rhythms in Per2Luc 
knock-in mice are not compromised by the knock-in construct. Figure S4 presents PER2 western-
blot analyses supporting the bioluminescence data in main Figure 1. Figure S5 shows rhythmicity 
in intact, sham, rhythmic, and arrhythmic SCN-lesioned Per2Luc mice with Nissl staining confirming 
the presence or absence of SCN.  
 
2. Supplemental Experimental Procedures  
Experimental Procedure 1:  EEG recording and analysis in Per2Luc mice.  
Electroencephalogram and Electromyogram (EEG/EMG) surgeries were performed according to 
the methods described previously1 with minor changes. Briefly, EEG and EMG electrodes were 
implanted under deep ketamine/xylazine anesthesia (intraperitoneal injection, 75- and 10mg/kg, 
at a volume of 8ml/kg). Two gold-plated screws (diameter 1.1mm) served as EEG electrodes and 
were screwed into the skull over the right cerebral hemisphere (frontal: 1.7mm lateral to midline, 
1.5mm anterior to bregma; parietal 1.7mm lateral to midline, 1.0mm anterior to lambda). Four 
additional screws were used as anchor screws. Two semi-rigid gold wires were used for EMG 
electrodes and were inserted into the neck musculature along the back of the skull. The four 
electrodes were soldered to a connector and cemented to the skull. After recovery from surgery 
(4-7 days) mice were connected to a swivel contact through recording leads to which they could 
habituate for 7 days prior to the experiment. 
 Per2Luc mice (n=6 males, 3 months old), were recorded for 96 continuous hours of which the 
first 48h served as baseline followed by 6h of SD and recovery. EEG and EMG signals were 
amplified, filtered, and analogy-to-digital converted (200Hz). The behavioral states wakefulness 
 2 
(W), rapid eye movement sleep (REMS), and non-REM sleep (NREMS) were visually assigned for 
consecutive 4s epochs as described previously.1 EEG signals were subjected to a discrete Fourier 
transform (DFT) to determine EEG power density in the delta frequency range (i.e., delta power, 
1-4Hz) for 4s epochs scored as NREMS. Differences in absolute levels of delta power among 
individuals were accounted for by expressing it as a percentage of the mean delta power over the 
last 4h of the two baseline light periods. Delta power was averaged for 12 intervals to which an 
equal number of NREMS epochs contributed (i.e., percentiles) during the 12h light periods, for 6 
intervals during the 12h dark periods, and for 8 intervals during the 6h immediately following SD 
(recovery). Choice of the number of percentiles per recording segment depended on the amount 
of NREMS present. 
  
Experimental Procedure 2:  Western-blot analyses 
To assess changes in PER2 protein levels in brain and liver, mice were sleep deprived (ZT0-6) and 
then sacrificed together with their home-cage controls by cervical dislocation at ZT6, -8, and -12. 
Baseline levels were assessed also at ZT0 and -18 [males, 3-month old, n=2 and 3 / time point in 
B6 and homozygote mPer2Luc mice, respectively; total n=40). Liver and brain tissues were 
dissected and frozen immediately on dry ice. Then, tissues were homogenized at 4°C for 30min in 
RIPA lysis buffer (Tris-HCl 50mM pH7.4; NaCl 150mM; EDTA 1mM; NP-40; Na-deoxycholate 10%; 
and one complete mini protease inhibitor mixture tablet for 50ml, Roche) and homogenates were 
cleared by centrifugation for 10min at 13’000rpm and 4°C. Protein concentration was calculated 
using the bicinchoninic acid assay (Pierce, Rockford, IL, USA) with BSA as a reference. 100 μg of 
protein were then mixed with an equal volume of loading buffer (glycerol 20%; SDS4%; Tris 
100mM; β-mercaptoethanol 5%; and bromophenol blue) before being heated to 98°C for 5min. 
Proteins were loaded on 8% SDS-polyacrylamide gel electrophoresis and transferred on a 
nitrocellulose membrane (Millipore) in transfer buffer (Glycine 192mM, Tris 25mM and methanol 
20%). 
 Membranes were then incubated with anti-mPER2 antibodies overnight at 4°C (for liver: 
rabbit anti-mPER2, 1:1000, generously provided by David Weaver, University of Massachusetts 
Medical School; for brain: rabbit anti-mPER2, 1:5000; generously provided by Ueli Schibler, 
University of Geneva). After washing, membranes were incubated with peroxidase-conjugated 
secondary anti-rabbit antibody (1:10000; Promega) 2h at RT. Blots were then developed using 
chemoluminescence ECL substrate (Amersham Life Science, Piscataway, NJ, USA). Membranes 
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were stripped with RestoreTM blot stripping buffer (Pierce), washed and incubated one night at 
4°C with rabbit polyclonal anti-tubulin (1:5000; Abcam, Cambridge, MA, USA) used as internal 
control. Quantification of the bands was carried out by densitometric analysis using ImageJ 1.33u 
software. 
 
Experimental Procedure 3:  3D-reconstruction of bioluminescence source localization 
The source of bioluminescence from peripheral organs was localized using 3D-reconstruction 
(Living Image 3.0 software; Xenogen) (see Figure S2). Per2Luc mice (males, 3 months of age, n=4) 
were shaved completely. 3D reconstruction of the bioluminescence source was achieved by 
multiple images taken at 45°-increments around the mouse. At each angle three readings were 
made with long-pass filters set at λ=570-, 600-, and 660nm, respectively, followed by a structured 
light image to determine the 3D surface topography of each animal. With this information the 
Diffuse Luminescence Imaging Tomography (DLIT) algorithm (Igor image analysis software, 
Wavemetrics), which models photon transport in tissue, can localize photon source. For each 
view, surface topography is determined from phase shifts of parallel line patterns; i.e., structured 
light projected onto the surface. The partial surface meshes are then stitched together to produce 
a whole-animal surface mesh. This experiment was performed at ZT18 when PER2 protein 
expression in the periphery has been shown to be the highest.2 
 4 
3. Supplemental Figures 
 
 
 
 5 
Figure S1:  Circadian locomotor activity rhythms and sleep regulation in Per2Luc mice. A) Two 
double-plotted actograms of one Per2Luc (left) and one wild-type (right) male mice to illustrate 
that the Per2Luc construct does not impact activity profiles both under LD12:12 and DD conditions. 
Dark periods shown in grey. Activity recorded with passive infrared (PIR) sensors. The Per2Luc 
genetic background is C57Bl/6J. B) Mean (±1SEM) time course of EEG delta power during non 
rapid-eye-movement (NREM) sleep (left y-axis, upper graph) and time spent in NREM sleep (right 
y-axis, lower graph) recorded for 48h baseline (hours 0-48), 6h sleep deprivation (SD; ZT0-6; hours 
48-54), and 42h recovery (hours 54-96). EEG delta power was expressed as a % of the last 4h of 
the two baseline light periods to correct for inter-individual difference in EEG amplitude and is 
depicted by grey circles connected by thin black lines. Time spent in NREM sleep was calculated 
in minutes per recording hour and depicted by open circles connected by thin black lines. Thicker 
grey lines represent the mean time course over the 2 baselines re-plotted for each of the 4 
recording days facilitating the visual assessment of recovery-baseline differences. Grey areas 
delineate the 12h dark periods. Red filled symbols mark intervals for which SD and recovery values 
significantly deviated from corresponding baseline values (post-hoc, paired t-test, P<0.05). Since 
only very little NREM sleep was present during the SD, meaningful levels of EEG delta power 
during this state could not be determined during this period. EEG delta power quantifies the 
prevalence and amplitude of EEG delta oscillations (1-4 Hz) characteristic of NREM sleep. EEG 
delta power is in a quantitative and predictive relationship with time-spent-awake and asleep 
such that during NREM sleep following prolonged periods wakefulness (including SD) EEG delta 
power is high while during times when NREM sleep prevails, it decreases. For this reason EEG 
delta power has been widely used as a measure of homeostatic sleep need and sleep depth. 
Dynamics of EEG delta power and time spent in NREM sleep in Per2Luc mice and the rebound in 
both variables after SD were similar to those observed in C57Bl/6J mice [control data not shown 
here but see3-5]. See supplementary information for EEG/EMG surgeries and analysis. 
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Figure S2:  In vivo source localization of peripheral PER2 expression in Per2Luc mice.  A: 3D-
acquisition of bioluminescent signals was performed at ZT18 with different angular views (0-315° 
at 45° increments) to localize the bioluminescence source. Mini-pump introduced subcutaneously 
(white arrowheads in left-hand image) released luciferin in the periphery showing strongest 
signals in one ventral and two dorsal parts. After 3D-reconstitution (Living Image 3.0; Xenogen), 
strongest voxels were found to be superposed on the liver (ventral view; B) and in the kidneys 
(dorsal view; C). Note that the mini-pump releasing luciferin is also visible (two black arrowheads). 
D: Mean (± 1SEM) bioluminescence levels in brain (black), liver (brown), and kidney (green line) 
under baseline conditions taken daily at ZT3 for 21 days from the day of mini-pump implantation 
(i.e., day 0). The "experiment" window indicates the time frame (days 4-10) within which data 
were collected. Values were expressed as a percentage of the individual average bioluminescence 
during the days data were collected. 
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Figure S3:  Actogram of double-plotted locomotor activity of one individual Per2Luc male under 
12:12h light-dark conditions used to sample bioluminescence 15 times (red asterisks) over a 7-
day period under baseline conditions (days 1-4: ZT0, -12, -3, -15, -6, -18, -9, -21) and before (day 
6: ZT0, -6, -8, -12) and after a 6h sleep deprivation (SD; day 7: ZT6, -8, -12). Red diamond indicates 
time of mini-pump implantation. Grey areas delineates the dark period. Note that imaging did not 
importantly alter the nycthemeral organization of activity. 
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Figure S4:  Western-blot analysis of the effects of sleep deprivation and time-of-day on PER2 levels 
in brain and liver tissues.  Whole brain protein extracts in C57BL/6J mice (A and B) and whole liver 
protein extracts in Per2Luc mice (C and D) at ZT0 (double plotted at ZT24), -6, -8, -12, and -18 during 
baseline conditions and 0- , 2- , and 6h after a 6h sleep deprivation (SD; ZT0-6); i.e., at ZT6 (6-SD), 
-8 (8-SD), and -12 (12-SD) were used. Protein extracts were incubated with antibodies against 
mPER2 and mTubulin as an internal control (panels A and C). Panels B and D depict densitometric 
quantification of band intensity expressed as percentage of the 24h-baseline mean. Grey lines 
connect baseline level, black lines recovery from SD, grey areas delineate the dark periods.  
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Figure S5:  Actograms, periodograms, and histology for SCN-lesioned (SCNx) Per2Luc mice and their 
controls. A: Double plot of locomotor activity for intact mice, sham-operated mice, and rhythmic 
and arrhythmic SCNx Per2Luc mice. Mice were recorded under 12:12h light-dark conditions for at 
least 16 days and under constant darkness for at least 17 days in order to verify rhythmicity of 
each animal. Red stars indicate the time corresponding to the surgery. In sham-operated mice 
electrodes were inserted but no electrical current was applied. Grey areas delineates the dark 
period. B: Chi-square periodograms (ClockLab analysis software) for the four groups of mice. Grey 
line marks the Chi-square 5% confidence level. Note that weak but significant circadian 
rhythmicity was observed in mice with partial SCNx (see C). Also note different scaling of y-axes. 
C: Coronal brain sections performed at two levels of the SCN (-0.46 and -0.82 mm with bregma as 
a reference according to 6) in the four groups of mice. Nissl staining in coronal brain section show 
the absence, partial, and entire presence of the SCN in SCNx-arrhythmic, SCNx-rhythmic, sham, 
and intact Per2Luc mice, respectively. Abbreviations: SCh = SCN; 3V = Third cerebral ventricle; f = 
fornix; PVN = Paraventricular nucleus; opt = optic chiasm. Scale bar = 200μm. 
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